34th week of 2012 patent applcation highlights part 33 |
Patent application number | Title | Published |
20120213683 | METHOD FOR TREATING EXHAUST GAS FROM CO2 RECOVERY APPARATUS - Provided is a method capable of removing a low concentration of amines contained in an exhaust gas that is discharged from a CO | 2012-08-23 |
20120213684 | COMBUSTION OF CO AND COMBUSTIBLES IN STEEL FURNACE OFFGASES - A hot oxygen stream containing radicals is fed into an offgas stream from a steelmaking vessel to convert carbon monoxide in the offgas to carbon dioxide. | 2012-08-23 |
20120213685 | OPTICAL MEMBER FOR DEEP ULTRAVIOLET AND PROCESS FOR PRODUCING SAME - The present invention relates to an optical member for deep ultraviolet having a wavelength of 250 nm or shorter, containing a synthetic silica glass which does not substantially contain a halogen element, has a maximum OH group content of less than 10 ppm by weight, has contents of ODC (oxygen deficient centers) and E-prime center of each less than 1×10 | 2012-08-23 |
20120213686 | MICROCHANNEL STRUCTURE, AND METHODS FOR PRODUCING EMULSION AND SOLID SPHERICAL PARTICLES - A microchannel structure is provided wherein supplied fluids are prevented from transuding via a lamination interface into channels for a mixture or reaction product. A method is further provided for producing an emulsion having a uniform particle size under a high pressure condition by using the microchannel structure. The microchannel structure comprises one or more layers having notches to constitute channels, laminated and pressed between a pair of frames having an outside communicating hole to constitute a channel, so as to form microchannels to mix/react fluids, channels to supply the fluids to the microchannels, and a channel to discharge the fluids from the microchannels, wherein a channel for discharging a transudation fluid is provided to recover a fluid having transuded at a lamination interface so as not to let it enter into the channels including the microchannels and discharge it to the outside. | 2012-08-23 |
20120213687 | METHOD FOR MANUFACTURING TRICHLOROSILANE - A method for manufacturing trichlorosilane in which hydrogen chloride and polymers including high-boiling chlorosilanes generated in a polycrystalline silicon manufacture process, a trichlorosilane manufacture process, or a conversion process are introduced into a decomposition furnace and are decomposition reacted at a high temperature, the method including: heating the decomposition furnace and a fin provided in the decomposition furnace; supplying the polymers and the hydrogen chloride to the decomposition furnace from an upper portion thereof so as to react the polymers and the hydrogen chloride by leading to an inner-bottom portion of the decomposition furnace while heating and stirring; and discharging a reacted gas from the inner-bottom portion upwardly above the decomposition furnace through a center of the decomposition furnace. | 2012-08-23 |
20120213688 | METHODS OF SEQUESTERING CO2 - Methods of sequestering carbon dioxide (CO | 2012-08-23 |
20120213689 | Selective Salt Recovery from - A process is provided for recovering sodium chloride crystals and sodium carbonate decahydrate crystals from a concentrated brine that results from a gas mining operation where gas and produced water is recovered and the produced water constitutes a brine. An initial pre-concentration process is carried out where the brine is concentrated and in the process carbon dioxide is removed from the brine and at least some sodium bicarbonate is converted to sodium carbonate. In one process, the concentrated brine is directed to a sodium chloride crystallizer where the brine is heated and further concentrated to form sodium chloride crystals which are separated from the brine to yield a product and wherein the resulting brine is termed a first mother liquor. The first mother liquor is then directed to a sodium carbonate decahydrate crystallizer where the first mother liquor is cooled and concentrated resulting in the formation of sodium carbonate decahydrate crystals and a second mother liquor. The second mother liquor is split into two streams where one stream is directed back to the sodium chloride crystallizer while the other stream is wasted or further treated. | 2012-08-23 |
20120213690 | Integration of Catalytic SO2 Oxidation and Oxyfuel Sour Compression - Sulfur dioxide (SO | 2012-08-23 |
20120213691 | GRAPHITE NANO-CARBON FIBER AND METHOD OF PRODUCING THE SAME - According to one embodiment, there is provided a graphite nano-carbon fiber provided by using an apparatus having a reactor capable of keeping a reducing atmosphere inside thereof, a metal substrate arranged as a catalyst in the reactor, a heater heating the metal substrate, a pyrolysis gas source supplying pyrolysis gas obtained by thermally decomposing a wood material in a reducing atmosphere to the reactor, a scraper scraping carbon fibers produced on the metal substrate, a recovery container recovering the scraped carbon fibers, and an exhaust pump discharging exhaust gas from the reactor. The carbon fibers are linear carbon fibers with a diameter of 25 to 250 nm formed with layers of graphenes stacked in a longitudinal direction. | 2012-08-23 |
20120213692 | DISTILLATION PROCESS FOR SEPARATING CHLORINE FROM GAS STREAMS COMPRISING OXYGEN AND CHLORINE - The invention relates to a process for separating chlorine from a gas stream I comprising oxygen and chlorine, in which the gas stream I is fed into a lower part of a column K | 2012-08-23 |
20120213693 | USE OF LIQUID HYDROGEN CHLORIDE AS REFRIGERANT IN PROCESSES FOR PREPARING CHLORINE - This invention relates to a process for preparing chlorine from HCl and a method of using liquid HCl to cool and optionally liquefy chlorine in the process. The process involves introducing at least one HCl-containing stream and an oxygen-containing stream into an oxidation zone and catalytically oxidizing the HCl to chlorine, contacting the chlorine with aqueous HCl with partial separation of water and HCl to yield a gas stream, drying the gas stream to yield an essentially water-free gas stream, which is compressed and cooled to give an at least partially liquefied stream, and separating the liquefied stream into a gas stream and a liquid stream which is separated into a chlorine stream, such that cooling and partial liquefaction of the gas stream is effected by indirect heat exchange with a liquid HCl stream, resulting in some of the liquid HCl stream vaporizing to form a gaseous HCl stream. | 2012-08-23 |
20120213694 | H2S CONVERSION TO SULFUR USING A REGENERATED IODINE SOLUTION - Systems and methods of removing sulfur from a gas stream comprising hydrogen sulfide (H | 2012-08-23 |
20120213695 | MODIFIED MOLECULAR SIEVE CHARACTERIZED BY IMPROVED SODIUM-RESISTING CONTAMINATION ACTIVITY AND PREPARATION METHOD THEREOF - Modified molecular sieve characterized by improved sodium-resisting contamination activity and preparation method thereof are provided. The method comprises: adding molecular sieve in phosphorus-containing organic solution, and reacting for 10-200 minutes at temperature of 70-200° C. and pressure of 0.2-1.2 MPa, and then filtering, drying and calcining. The said modified molecular sieve contains 90-99 wt. % molecular sieve as dry basis and 1-10 wt. % phosphorus as oxide. The said method can improve the capability of sodium-resisting contamination effectively, and its technology is simple and fits the existing catalyst production apparatus and process. The said modified molecular sieve has high sodium-resisting contamination activity, and the model catalyst by sodium contamination has high activity retention. | 2012-08-23 |
20120213696 | PROCESS FOR PRODUCTION OF DDR-TYPE ZEOLITE - There is provided a process for producing a DDR-type zeolite having: a raw material solution preparation step of preparing a raw material solution containing 1-adamantaneamine hydrochloride, silica (SiO | 2012-08-23 |
20120213697 | VERSATILE NANOPARTICULATE BIOMATERIAL FOR CONTROLLED DELIVERY AND/OR CONTAINMENT OF THERAPEUTIC AND DIAGNOSTIC MATERIAL - The invention provides compositions for controlled delivery and/or containment of therapeutic and/or diagnostic agents comprising the agent or agents encapsulated by a matrix containing chitosan, polyethylene glycol (PEG) and/or polyvinyl alcohol (PVA), and tetra-methoxy-ortho-silicate (TMOS) or tetra-ethoxy-ortho-silicate (TEOS), as well as methods for preparing the compositions, and uses of the compositions for therapy and imaging. | 2012-08-23 |
20120213698 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES - The present invention relates to a novel composition and method for loading delivery systems such as liposome compositions with radionuclides useful in targeted diagnostic and/or therapy of target site, such as cancerous tissue and, in general, pathological conditions associated with leaky blood vessels. The composition and methods of the invention find particular use in diagnosing and imaging cancerous tissue and, in general, pathological conditions associated with leaky blood vessels in a subject. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. One specific aspect of the invention is directed to a method of producing nanoparticles with desired targeting properties for diagnostic and/or radio-therapeutic applications. | 2012-08-23 |
20120213699 | SINGLE CHAIN FRAGMENT OF MONOCLONAL ANTIBODY 9B9 AND USES THEREOF - Anti-ACE single chain fragment antibodies are disclosed. The present invention relates to using these antibodies, and polymers thereof, in methods for detecting, diagnosing, prognosing, preventing, or treating diseases associated with ACE expressing tissue. | 2012-08-23 |
20120213700 | COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN - The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce | 2012-08-23 |
20120213701 | METHODS FOR TUMOR DIAGNOSIS AND THERAPY - The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule. | 2012-08-23 |
20120213702 | NOVEL DIAGNOSTIC AGENTS FOR THE NON-INVASIVE IN VIVO IMAGING OF AMINOPEPTIDASE N (APN/CD13) - The present invention relates to aminopeptidase N (APN) inhibitor conjugates of formula I wherein W is a —CO— or an —SO | 2012-08-23 |
20120213703 | RADIOLABELLED PDE10 LIGANDS - The present invention relates to novel, selective, radiolabelled PDE10 ligands which are useful for imaging and quantifying the PDE10A enzyme in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo. | 2012-08-23 |
20120213704 | SYSTEM AND METHOD FOR MOLECULAR IN VIVO IMAGING AND THERANOSTICS - Systems and methods of characterizing biological tissues are provided. In the systems and methods, a first optical coherence tomography (OCT) image of a selected portion of biological tissues combined with a plurality of nanoparticles is obtained, where the plurality of nanoparticles are configured to bind to one or more types of biological molecules in the biological tissues and to produce contrast during OCT imaging. The systems and methods also include estimating a first distribution of the plurality of nanoparticles in the selected portion based on the first OCT image and characterizing the selected portion with respect to the types of biological molecules based on the distribution. | 2012-08-23 |
20120213705 | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION - Fc regions useful for site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such Fc regions are also provided. | 2012-08-23 |
20120213706 | RECONSTITUTED TUMOR MICROENVIRONMENT FOR ANTICANCER DRUG DEVELOPMENT - Extracellular matrix bioscaffolds capable of supporting the formation and growth of tumors from tumor cells introduced thereto containing tumor associated macrophages and carcinoma-associated fibroblast-like cells cultured under conditions effective to provide a cellular matrix capable of supporting the formation and growth of tumors from tumor cells introduced to the matrix. Bioscaffold kits and methods for using the bioscaffolds for testing, identifying and development of known or novel anti-cancer therapeutics are also disclosed. | 2012-08-23 |
20120213707 | Riboflavin Based Aerosol and Use as Placebo in Trials - A method for evaluating an aerosolized test compound includes administering a test compound to a first population of individuals, via inhalation of an aerosol; administering a placebo comprising riboflavin 5′-phosphate to a second population of individuals, via inhalation of an aerosol; and comparing a biological marker for the individuals in the two populations. An aerosol comprising riboflavin 5′-phosphate (also known as flavin mononucleotide) may be used either as a placebo in clinical trials, or therapeutically. | 2012-08-23 |
20120213708 | HYDROGEL ENCAPSULATED CELLS AND ANTI-INFLAMMATORY DRUGS - A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject. | 2012-08-23 |
20120213709 | Non Surfactant Hydro-Alcoholic Foamable Compositions, Breakable Foams and Their Uses - A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions. | 2012-08-23 |
20120213710 | Non Surface Active Agent Non Polymeric Agent Hydro-Alcoholic Foamable Compositions, Breakable Foams and Their Uses - A substantially surface active agent-free and substantially polymeric agent-free foamable composition which includes short-chain alcohol, water, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free and substantially polymeric agent-free foamable composition which includes water, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free and substantially polymeric agent-free foamable composition. | 2012-08-23 |
20120213711 | Compositions Containing A Solvated Active Agent Suitable For Dispensing As A *** Gas Aerosol - A composition for solvating one or more active agents in an aqueous solution which is suitable for dispensing as a compressed gas aerosol composition is disclosed. The composition includes at least one surfactant, at least one active agent, and a compressed gas propellant. The at least one surfactant is preferably present in an amount from about 0.1 wt. % to about 3 wt. %. The at least one active agent is preferably present in an amount from about 0.1 wt. % to about 2 wt. %. The compressed gas propellant is preferably present in an amount from about 0.1 wt. % to about 1 wt. %. The total surfactant weight to active agent weight ratio for the composition is preferably about 1:3 to 5:1. The composition uses a reduced amount of surfactant and active agent thereby allowing for a more efficient active agent loading and a reduced stickiness or tackiness on surfaces contacted during use. | 2012-08-23 |
20120213712 | COSMETIC COMPOSITION IN THE FOAM FORM - The present invention relates to a cosmetic composition in the foam form comprising, in a physiologically acceptable medium, at least one aqueous phase, talc and one UV sunscreen ingredient. It also relates to a cosmetic composition in the foam form comprising, in a physiologically acceptable medium, at least one aqueous phase, at least 1% by weight of at least one mineral filler relative to its total weight, and one UV sunscreen ingredient. | 2012-08-23 |
20120213713 | Compositions of omega fatty acids for the prevention and treatment of dental caries resulting from oral infections - The present invention discloses compositions of omega polyunsaturated fatty acids for controlling and preventing dental caries resulting from oral infections. The compositions of fatty acids include omega-3 fatty acids, omega-6 fatty acids, and other fatty acids, for their synergistic bioactivity against cariogenic pathogens. The application of this composition can be used for the preparation of drugs, nutritional supplements, food and daily necessities with oral health care and therapeutic effects. | 2012-08-23 |
20120213714 | Method and compositions as an adjunct for the prevention and treatment of periodontal disease - The present invention discloses compositions of omega fatty acids as an adjunct for controlling and preventing periodontal disease. The application of these compositions can be used for the preparation of drugs, dietary supplements, food, nutrition, and daily necessities with oral health care and therapeutic effects. | 2012-08-23 |
20120213715 | Method and composition for the prevention and treatment of early childhood dental caries - The present invention discloses a composition of omega polyunsaturated fatty acids for controlling and preventing early childhood dental caries. The application of this composition can be used for the preparation of drugs, nutritional supplements, food and daily necessities with oral health care and therapeutic effects for children. | 2012-08-23 |
20120213716 | METHOD FOR ALLEVIATING THE UNDESIRED SIDE EFFECTS OF DENTAL BLEACHING - The present invention relates to a method for reducing or eliminating loss of minerals from the enamel and dental hypersensitivity against temperature changes, in particular when caused by the bleaching of teeth with products containing hydrogen peroxide or other oxidizing agents. After the bleaching process the teeth are treated with a calcium hydroxide containing solution, and subsequently the teeth are treated with a fluoride solution. | 2012-08-23 |
20120213717 | Soothing Agents - In certain embodiments, the present invention is directed to the use of soothing agents to relieve mild irritation and/or enhance the overall soothing, comfort or refreshing feel of mucosal membranes of the eye, oral cavity, otic, nose, throat or vaginal area. The present invention further relates to compositions, articles and methods for masking or reducing the irritant properties of sensory compounds, such as terpenes and/or phenolic agents. | 2012-08-23 |
20120213718 | METHOD FOR ADDING ACTIVE INGREDIENTS TO A NAIL VARNISH AND NAIL VARNISH THUS PREPARED - A method for adding active agents to a nail varnish, in emulsion form. The method is suitable for adding active agents by minimizing the breakdown of same in the varnish, or the destabilization of the varnish. The method also enables the addition of active ingredients that were previously incompatible with the varnish medium. | 2012-08-23 |
20120213719 | COSMETIC COMPOSITION FOR SKIN WHITENING - The present invention relates to a cosmetic composition for skin whitening containing at least two selected from the group consisting of a | 2012-08-23 |
20120213720 | Prodrug composition for skin with twin protecting groups bound by disubstituted benzene - A prodrug composition for skin with twin protecting groups bound by disubstituted benzene is disclosed. The prodrug composition is a derivative of 1,4-bis(tetrahydro-2H-pyran-2-yloxy)benzene. Thereby, the twin protecting groups endow the prodrug composition with improved duration of action and efficiency to a targeted object such as melanocytes or tyrosinase, so as to facilitate distributing the prodrug composition over the stratum basale, in turn promoting melanocytes' absorption and tyrosinase's transportation as well as metabolism. | 2012-08-23 |
20120213721 | Amphiphilic High Refractive Index Organopolysiloxanes - Amphiphilic silicons which are dispersible or self-dispersing in water, have a high refractive index, and are prepared by a hydrosilylation reaction, resulting in products which are free of cyclic organopolysiloxanes. The high refractive index and dispersibility make the amphiphilic silicones useful in personal care and cosmetics where high shine or gloss is desired. | 2012-08-23 |
20120213722 | Combined Stable Cationic And Anionic Surfactant Compositions - Aqueous free-flowing surfactant compositions having non-Newtonian shear thinning properties are disclosed. These stable compositions include both cationic and anionic surfactants and can suspend water-insoluble particles or partially insoluble components. | 2012-08-23 |
20120213723 | HEAT ACTIVATED DURABLE STYLING COMPOSITIONS COMPRISING SACCHARIDE TYPE COMPOUNDS AND FILM FORMING AGENTS - A composition for durable non-permanent shaping or durable retention of a non-permanent shape of least one keratinous fiber comprising:
| 2012-08-23 |
20120213724 | AGENT FOR TEMPORARILY STYLING KERATIN-CONTAINING FIBRES CONTAINING A NON-IONIC STARCH MODIFIED BY PROPYLENE OXIDE AND A CHITOSANE - Cosmetic agents for the temporary deformation of keratinic fibers which contain, in a cosmetic carrier, a combination of at least one chitosan compound and at least one nonionic starch modified by means of propylene oxide, produce a hairstyle with a high degree of hold, excellent flexibility, and good hair care. | 2012-08-23 |
20120213725 | Surfactant-Polymer Blends - The present invention relates to surfactant-polymer blends that are useful as thickeners for a variety of personal care products. In one embodiment, the surfactant-polymer blends of the present invention comprises: (a) at least one anionic surfactant; (b) at least one amphoteric or zwitterionic surfactant; and (c) at least one hydrophobically-modified polymer formed from a mixture comprising: (i) an α,β-ethylenically unsatured carboxylic acid monomer; (ii) a nonionic, co-polymerizable α,β-ethylenically unsaturated monomer; and (iii) an ethylenically unsaturated hydrophobically-modified associative monomer. The surfactant-polymer blends of the present invention are useful as thickeners in a variety of products including, but not limited to, personal care products, health care products, household care products, institutional and industrial care products, and industrial applications. | 2012-08-23 |
20120213726 | BIO-BASED LINEAR ALKYLPHENYL SULFONATES - The invention is directed to mixtures comprising C | 2012-08-23 |
20120213727 | THERAPEUTIC USES OF OLIGOMERIC AND POLYMERIC MONOTERPENES - The invention relates to therapeutic methods comprising use of oligomeric and polymeric forms of the monoterpene compounds alloocimene, limonene, alpha-pinene, beta-pinene, geranyl acetate, alpha-phellandrene, gamma-terpinene, 3-carene and 2-carene. More particularly, the invention relates to methods of treating degenerative neurological conditions, and treating skin disorders. | 2012-08-23 |
20120213728 | GRANULOCYTE-COLONY STIMULATING FACTOR PRODUCED IN GLYCOENGINEERED PICHIA PASTORIS - Compositions comprising granulocyte-colony stimulating factor (GCSF) produced in a strain of | 2012-08-23 |
20120213729 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2012-08-23 |
20120213730 | ALTERATION OF CELL MEMBRANE FOR NEW FUNCTIONS - Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis. | 2012-08-23 |
20120213731 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES - The invention features methods for increasing or maintaining the number of functional cells of a predetermined type, for example, insulin producing cells of the pancreas, blood cells, spleen cells, brain cells, heart cells, vascular tissue cells, cells of the bile duct, or skin cells, in a mammal (e.g., a human patient) that has injured or damaged cells of the predetermined type. | 2012-08-23 |
20120213732 | TARGETED DELIVERY OF ANTIVIRAL COMPOUNDS THROUGH HEMOGLOBIN BIOCONJUGATES - This invention relates to targeted delivery of anti-viral compounds through protein bioconjugation. More particularly, it relates to an anti-viral compound conjugated to a protein, such as hemoglobin and to a method of treating a viral infection using said conjugate. The invention also provides a method of targeted drug delivery of an anti-viral nucleoside analogue to macrophages, cells comprising a hemoglobin receptor and to CD163 bearing cells. | 2012-08-23 |
20120213733 | ANTI-INFECTIVE AGENTS AND USES THEREOF - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 2012-08-23 |
20120213734 | Method for Cancer Therapy Based on a Co-Administration of a Parvovirus and a Cytokine - Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a cytokine, preferably IFN-γ, and the use of said composition for treatment of cancer, e.g., a brain tumor. | 2012-08-23 |
20120213735 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES - The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula I, II, and III are useful as anti-viral agents and/or as anti-cancer agents. | 2012-08-23 |
20120213736 | PARVOVIRUS METHODS AND COMPOSITIONS FOR KILLING NEOPLASTIC CELLS - According to the invention, parvoviruses such as the adeno-associated virus Type 2 (AAV2) are found to be oncolytic, selectively mediating apoptosis in cancer cells and their precursors, while leaving healthy cells intact. The invention also includes a method of killing cancer and other neoplastic and preneoplastic cells by administrating to said cells the AAV2 proteins Rep78 or Rep 68, expression constucts encoding the same, or pharmaceutical compositions comprising the same. | 2012-08-23 |
20120213737 | COMPOSITIONS AND METHODS FOR THERAPEUTIC MEMBRANE REPAIR - Disclosed herein are compositions comprising PTRF polypeptides, nucleic acids, and PTRF binding proteins useful for tissue regeneration and the treatment and prevention of disorders relating to cell membrane damage and repair. | 2012-08-23 |
20120213738 | Cardiac Repair By Reprogramming of Cardiac Fibroblasts Into Cardiomyocytes - The present invention involves the use of transcription factors including Tbx5, Mef2C, Hand2, myocardin and Gata4 to reprogram cardiac fibroblasts into cardiomyocytes, both in vitro and in vivo. Such methods find particular use in the treatment of patients post-myocardial infarction to prevent or limit scarring and to promote myocardial repair. | 2012-08-23 |
20120213739 | METHOD TO GROW LAWSONIA INTRACELLULARIS BACTERIA IN PERSISTENTLY INFECTED MCCOY CELLS - The present invention pertains to a method to obtain McCoy cells persistently infected with | 2012-08-23 |
20120213740 | Novel Granular Bioplastic Biocontrol Composition - Previous research demonstrated that aflatoxin contamination in corn is reduced by field application of wheat grains pre-inoculated with the non-aflatoxigenic | 2012-08-23 |
20120213741 | COMMERCIAL SCALE PROCESS FOR PRODUCTION OF PRRSV - The present invention describes an efficient commercial scale production method for the preparation of PRRS virus. | 2012-08-23 |
20120213742 | VIRUS GROWING IN HYPOXIC CELL OR VIRUS VECTOR EXPRESSING GENE THEREIN - The present invention provides a virus or a viral vector capable of expressing a gene specifically in a cell having replication ability in a hypoxic state such as a cancer stem cell and injuring the cell, and a pharmaceutical composition comprising the same. Specifically, the present invention provides a virus or a viral vector which comprises a gene encoding a fusion protein of an ODD and a protein essentially required for viral proliferation, and a pharmaceutical composition comprising the same. | 2012-08-23 |
20120213743 | TREATMENT OF PERIPHERAL VASCULAR DISEASE USING UMBILICAL CORD TISSUE-DERIVED CELLS - Compositions and methods of using cells derived from umbilical cord tissue, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed. In particular, methods of treating a patient having a peripheral vascular disease with umbilical derived cells and fibrin glue are disclosed. | 2012-08-23 |
20120213744 | COMPOSITIONS AND METHODS FOR MODULATING STEM CELLS AND USES THEREOF - There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells, e.g. satellite stem cells, to activate the planar cell polarity (PCP) pathway, thereby promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue. | 2012-08-23 |
20120213745 | SERUM-FREE MEDIA AND THEIR USES FOR CHONDROCYTE EXPANSION - The present invention provides defined serum-free cell culture media useful in culturing fibroblasts, especially articular chondrocytes, that avoid problems inherent in the use of serum-containing media. The defined media comprise platelet-derived growth factor (PDGF), chemically defined lipids, oncostatin M (OSM), interleukin-6 (IL-6), leukemia inhibitory factor (LIF), or combinations of these compounds. In another aspect, the present invention also provides tissue culture methods that comprise incubating chondrocytes in the defined serum-free media. The methods enhance attachment and proliferative expansion of chondrocytes seeded at low density while maintaining their redifferentiation potential. | 2012-08-23 |
20120213746 | METHOD AND COMPOUNDS FOR GENERATION OF iPSCs - The present invention is based on the seminal concept of combining genomics and chemical biology to identify new agents useful for induced pluripotent stem cell (iPSC) generation. The invention provides a method of generating an iPSC utilizing agents that antagonize a cell specific gene or upregulate expression or activity of a nuclear reprogramming gene, as well as a method of screening for such agents. | 2012-08-23 |
20120213747 | METHODS OF REDUCING TRANSPLANT REJECTION AND CARDIAC ALLOGRAFT VASCULOPATHY BY IMPLANTING AUTOLOGOUS STEM CELLS - The invention provides novel methods of reducing transplant rejection and cardiac allograft vasculopathy in humans by employing the implantation of autologous progenitor cells into the transplanted donor heart. The autologous progenitor cells can be vascular progenitor cells (VPCs) and/or myocyte progenitor cells (MPCs) isolated from the recipient's explanted heart. Alternatively, bone marrow progenitor cells (BMPCs) isolated from the recipient may also be used. | 2012-08-23 |
20120213748 | CARDIOMYOCYTES AND METHODS OF PRODUCING AND PURIFYING CARDIOMYOCYTES - The invention provides methods for producing a culture of cardiomyocytes and cultures of cardiomyocytes. Exemplary methods of producing and cultures of cardiomyocytes include a population of cells including cells having spontaneous and periodic electrical activity, and/or including nodal, sino-atrial or pacemaker cells; immature cardiomyocytes (cardiomyoblasts); mature contractile cardiomyocytes; or a mixed population of two or more of such cells. | 2012-08-23 |
20120213749 | CARDIAC MUSCLE REGENERATION USING MESENCHYMAL STEM CELLS - Disclosed is a method for repairing or regenerating blood vessels in the heart of an individual, method of stimulating or promoting angiogenesis in the heart of an individual, or method of stimulating or promoting vascular endothelial growth factor (VEGF) expression in a heart of an individual by administering to the individual an effective amount of mesenchymal stem cells. These cells can be administered as a liquid injectable. | 2012-08-23 |
20120213750 | USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA - Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae. | 2012-08-23 |
20120213751 | NOVEL STEM CELLS, NUCLEOTIDE SEQUENCES AND PROTEINS THEREFROM - The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5− stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein. | 2012-08-23 |
20120213752 | ISOLATED STROMAL CELLS AND METHODS OF USING THE SAME - Isolated stromal cells, containers comprising isolated stromal cells transfected with exogenous DNA, and methods of treating patients suffering from diseases characterized by a bone cartilage or lung defect are disclosed. The methods comprise obtaining a bone marrow sample from a donor, isolating stromal cells from the sample, and administering the isolated stromal cells to the patient. | 2012-08-23 |
20120213753 | LACTOBACILLUS PLANTARUM STRAINS AS HYPOCHOLESTEROLEMIC AGENTS - The invention relates to a composition comprising an effective amount of at least one of the strains selected from the group consisting of | 2012-08-23 |
20120213754 | Method of Preconditioning of Cell Suspensions - An apparatus for the preparation of cells for implantation into a living body is disclosed. The apparatus comprises a vessel substantially impermeable to gaseous oxygen; and fluid within said vessel, the fluid having a maximal dissolved oxygen capacity substantially equivalent to normal saline yet having a hypoxic oxygen concentration between about 0% to about 5% of said maximal dissolved oxygen capacity. The bag oxygen concentration level remains low when the apparatus is stored at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days. The present invention simplifies the process of achieving donor cell hypoxic preconditioning for cell implantation, and may be used to bathe said cells to be transplanted for a sufficient time to activate the hypoxic metabolic pathway. | 2012-08-23 |
20120213755 | SEMI-SYNTHETIC PLATELET GEL AND METHOD FOR THE PREPARATION THEREOF - A semi-synthetic platelet gel comprising a platelet-rich plasma, at least one platelet activator, and a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof. | 2012-08-23 |
20120213756 | NUTRACEUTICAL BEVERAGE - A nutraceutical composition for humans and/or animals containing three main components: water, | 2012-08-23 |
20120213757 | NUTRITIONAL SUPPLEMENT COMPOSITION - New dietary supplement composition comprising, as active ingredients:
| 2012-08-23 |
20120213758 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS - The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id: | 2012-08-23 |
20120213759 | ANTIMICROBIAL CLEANING AGENT FOR HARD SURFACES - A surfactant-containing aqueous antimicrobially effective cleaning agent for hard surfaces includes at least one amphoteric polymer, a quaternary ammonium compound and formic acid. The agent may be used for the cleaning and/or antimicrobial treatment of hard surfaces, in particular in damp rooms such as bathrooms. | 2012-08-23 |
20120213760 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYOTUBULAR MYOPATHY USING CHIMERIC POLYPEPTIDES COMPRISING MYOTUBULARIN 1(MTM1) POLYPEPTIDES - The present invention provides chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides and an internalising moiety, wherein, the moiety can be an antibody, and is preferably monoclonal antibody 3E10, a functional variant or a fragment thereof. One aspect of the present invention provides compositions comprising these chimeric polypeptides together with a pharmaceutically acceptable carrier, and optionally, a further therapeutic agent. Another aspect of the present invention provides methods of treating Myotubular Myopathy comprising administering the polypeptides or compositions comprising the polypeptides to a subject in need. | 2012-08-23 |
20120213761 | USE OF GSTP1 - The invention discloses the use of glutathione S-transferase P1 (GSTP1) for the prevention or treatment of cardiomyopathies or ischemic heart diseases and for the diagnosis thereof. | 2012-08-23 |
20120213762 | LYSOSOMAL TARGETING PEPTIDES AND USES THEREOF - The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor. | 2012-08-23 |
20120213763 | MUTANTS OF STREPTOKINASE AND THEIR COVALENTLY MODIFIED FORMS - The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates. Disclosed herein are site-specific biologically active conjugates of Streptokinases and its covalently modified variants. | 2012-08-23 |
20120213764 | NOVEL METHOD FOR THE PRODUCTION OF A ANTIMICROBIAL PEPTIDE - The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b). | 2012-08-23 |
20120213765 | METHOD AND COMPOSITION MITIGATING FECAL AND FLATULENT ODORS - A method of mitigating or eliminating the odor associated with the feces or flatulence of an animate subject, whether human or animal, by means of administering activated carbon, whether alone or in composition with further inert ingredients, to the subject for ingestion and digestion of the same in advance of the subject either defecating or expelling flatulence. | 2012-08-23 |
20120213766 | Anticancer Compounds from Vernonia Guineensis - This invention relates to novel compounds with anticancer activity isolated from | 2012-08-23 |
20120213767 | Extended Soluble PH20 Polypeptides and uses thereof - Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof. | 2012-08-23 |
20120213768 | Diagnostic and Therapeutic Uses for B Cell Maturation Antigen - Biomarkers and therapies against autoimmune diseases, including systemic lupus erythematosus (SLE) are described herein. The present invention is based on the discovery of B cell maturation antigen (BCMA) and BCMA variant expression on SLE monocytes that can be directly associated with disease activity. The findings of the present invention enable the design of monoclonal antibodies or recombinant proteins that can block BCMA and BCMA variants as well as BCMA-bound APRIL. | 2012-08-23 |
20120213769 | METHODS OF DIAGNOSING AMYOTROPHIC LATERAL SCLEROSIS (ALS) - A method of diagnosing amyotrophic lateral sclerosis (ALS) in a subject in need thereof is provided. The method comprising determining in cells of the subject at least one alteration in a sequence or expression level of Cytoplasmic FMR Interacting Protein (CyFIP2; Accession AF160973) and/or Retinoblastoma Binding Protein 9 (RbBP9; Accession AF039564), wherein an altered sequence or expression of the sequence or expression level of the CyFIP2; Accession AF160973) or Retinoblastoma Binding Protein 9 (RbBP9; Accession AF039564) as compared to a control reference sample from a non-ALS subject, is indicative of ALS. The present teachings may be implemented in screening for novel anti-ALS medicaments and for treating ALS. | 2012-08-23 |
20120213770 | COMPOSTIONS AND METHODS FOR IDENTIFYING RESPONSE TARGETS AND TREATING FLAVIVIRUS INFECTION RESPONSES - Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-α is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-α secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%. | 2012-08-23 |
20120213771 | ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF - Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies. | 2012-08-23 |
20120213772 | Metabolic biomarkers of Crohn's Disease - The invention provides for a method for identifying a biomarker in a fecal sample of a subject in need of such identification comprising: determining whether a fecal sample collected from a subject comprises a biomarker. | 2012-08-23 |
20120213773 | BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS - The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins. | 2012-08-23 |
20120213774 | Antibodies against human IL33R and uses thereof - An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases. | 2012-08-23 |
20120213775 | TREATMENT OF RENAL DISEASES - Compositions for the treatment of renal diseases and disorders utilize agents which inhibit alphaV integrin molecules in vivo. Methods of treatment include use of these agents in the prevention and treatment of proteinuria, progressive glomerular disease and glomerular disease amongst others. | 2012-08-23 |
20120213776 | ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR - The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies. | 2012-08-23 |
20120213777 | VASCULAR ENDOTHELIAL GROWTH FACTOR 2 - Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof. | 2012-08-23 |
20120213778 | METHOD OF DETECTING AND TREATING TUBEROUS SCLEROSIS COMPLEX ASSOCIATED DISORDERS - Disclosed are methods of detecting and treating tuberous sclerosis complex associated disorders. Also disclosed are methods of identifying agents for treating tuberous sclerosis complex associated disorders. | 2012-08-23 |
20120213779 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 2012-08-23 |
20120213780 | Efficient mucosal vaccination mediated by the neonatal Fc receptor - The present invention relates to methods and compositions for enhancing delivery of vaccine antigens to the mucosal epithelium, the composition comprising an antigen from an infectious agent fused with an Fc fragment of an immunoglobulin recognized by the neonatal receptors (FcRn). The composition is effective in eliciting a protective long-term memory T cell immune response against infection at a distant mucosal site. | 2012-08-23 |
20120213781 | Monovalent and Multivalent Multispecific Complexes and Uses Thereof - Monovalent and multivalent multispecific complexes including ELP-MRD fusion proteins containing one or more modular recognition domains (MRDs) that bind target antigens are described. The use of these monovalent and multivalent multispecific complexes (e.g., ELP-MRD fusion proteins) in diagnostic, prognostic, and therapeutic applications and methods of making these complexes are also described. | 2012-08-23 |
20120213782 | BMP10 ANTIBODIES AND RELATED METHODS - In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10. | 2012-08-23 |